Overview Of Value Stocks In The Healthcare Sector
Portfolio Pulse from Benzinga Insights
The article provides an overview of value stocks in the healthcare sector, highlighting five notable companies with low P/E multiples. These stocks may be undervalued, but there is a risk that their prices may not rebound.
June 05, 2023 | 2:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Assertio Holdings has a low P/E multiple of 3.61 and reported Q1 earnings per share of $0.29, down from $0.32 in Q4.
Assertio Holdings has a low P/E multiple, indicating potential undervaluation. However, the stock's price may not rebound in the short term, and the risk of investing in a value stock is that the emergence may never materialize.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 100
NEUTRAL IMPACT
Cross Country Healthcare has a low P/E multiple of 6.42 and saw a decrease in earnings per share from 1.09 in Q4 to $0.84 now.
Cross Country Healthcare has a low P/E multiple, indicating potential undervaluation. However, the stock's price may not rebound in the short term, and the risk of investing in a value stock is that the emergence may never materialize.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 100
NEUTRAL IMPACT
Kiniksa Pharmaceuticals has a low P/E multiple of 5.26 and saw a decrease in earnings per share from 0.06 in Q4 to $-0.18 now.
Kiniksa Pharmaceuticals has a low P/E multiple, indicating potential undervaluation. However, the stock's price may not rebound in the short term, and the risk of investing in a value stock is that the emergence may never materialize.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 100
NEUTRAL IMPACT
Sensus Healthcare has a low P/E multiple of 7.3 and reported Q1 earnings per share of $-0.12, down 170.59% from $0.17 in Q4.
Sensus Healthcare has a low P/E multiple, indicating potential undervaluation. However, the stock's price may not rebound in the short term, and the risk of investing in a value stock is that the emergence may never materialize.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 100
NEUTRAL IMPACT
TherapeuticsMD has a low P/E multiple of 2.26 and saw an increase in earnings per share from -3.62 in Q4 to $-0.24 now.
TherapeuticsMD has a low P/E multiple, indicating potential undervaluation. However, the stock's price may not rebound in the short term, and the risk of investing in a value stock is that the emergence may never materialize.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 100